Study of lisaftoclax plus acalabrutinib for untreated CLL/SLL
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a new combination of two targeted drugs (lisaftoclax and acalabrutinib) against standard chemo-immunotherapy for people newly diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma who need treatment. It aims to see if the combination works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with CLL or SLL and need treatment.
- You have not had any prior treatment for CLL or SLL.
- You are able to perform daily activities with little to no help (ECOG score 0-2).
- Your heart, liver, kidneys, and blood counts are working well enough.
- You are not pregnant and agree to use effective birth control during the study and for 3 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial studies APG-2575 (alone or with other medicines) in adults with CLL/SLL whose disease came back or did not respond to earlier treatment. The goal is to learn the safest dose and whether it can shrink the leukemia and improve symptoms.
This trial tests a new drug called APG2575 for people with chronic lymphocytic leukemia or small lymphocytic lymphoma who have been taking a BTK inhibitor for at least 12 months. The goal is to see if adding APG2575 can help control the disease better.
This trial tests a combination of two targeted drugs for people with CLL or SLL whose cancer returned after first treatment with a similar type of therapy. The goal is to see if this approach works well with a fixed treatment duration.
This trial is testing a combination of three targeted drugs (tafasitamab, acalabrutinib, and venetoclax) for people with CLL or SLL who have not yet received treatment. The goal is to see if this combination is effective and manageable.
This trial tests a new drug called lisatoclax added to the usual chemotherapy and antibody treatment for people newly diagnosed with diffuse large B-cell lymphoma (DLBCL). The goal is to see if adding this drug helps the standard treatment work better.
This Phase 2 trial studies whether combining acalabrutinib and venetoclax can shrink or control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or did not respond to prior treatment. It may help by attacking the cancer using two different medicines together.
Hear when a new CLL/SLL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.